Arrowhead Research | ARWR - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Alnylam Pharmaceuticals USD 82.05M 12.76M 2026-06
Anika Therapeutics 183.47M 4.09M 2026-06
Arrowhead Research USD 24.56M 716K 2026-06
Heron Therapeutics USD 600K 100K 2024-12
Incyte USD 582K 13K 2026-06
Ionis Pharmaceuticals USD 18M 1000K 2026-06
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
Merck USD 525M 46M 2026-06
Moderna USD 10.96B 527M 2026-06
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Novartis USD 462M 119M 2026-06
Sarepta Therapeutics USD 21.51M 205K 2026-06
TG Therapeutics USD 16.57M 8.91M 2026-06
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Xencor USD 7.35M 2.65M 2026-06